TABLE 5.
Antiviral susceptibilities of reference CMV strains
| Methoda | Ganciclovir IC50 (μM) to:
|
Foscarnet IC50 (μM) to:
|
Cidofovir IC50 (μM) to:
|
Reference | |||
|---|---|---|---|---|---|---|---|
| AD169b | 759rD100c | AD169 | 759rD100 | AD169 | 759rD100 | ||
| PRA | 3.1 | 17 | |||||
| 1 | 12 | 150 | 150 | 6 | |||
| 4.9 | 35 | 64 | 24 | 0.6 | 61 | ||
| 4 | 210 | 0.54 | 64 | ||||
| 10 | 250 | 1 | 47 | ||||
| 5.3 | 58.9d | 52 | |||||
| 2.5 | 55 | 10 | |||||
| 10 | 200 | 0.5 | 48 | ||||
| 0.6 | 10 | ||||||
| DNA | 1.7 | 39 | 50 | 35 | 0.49 | 1.5 | 61 |
| 0.7 | 19 | 8 | |||||
| LARA | 6.5 | 31.6d | 52 | ||||
| ELISA | 5.4 | 150 | 67 | ||||
| 6.25 | 210 | 1 | 47 | ||||
PRA, plaque reduction assay; DNA, DNA hybridization assay; LARA, late-antigen reduction assay.
Susceptible CMV strain that contains UL97 and DNA polymerase wild-type sequences.
Ganciclovir-resistant CMV strain that contains a UL97 deletion and a DNA polymerase mutation.
Ganciclovir-resistant strain RCL1 was used.